Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAvMed Aduhelm prior auth & coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Aduhelm (aducanumab) prior authorization — medical necessity and monitoring criteria

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical prior authorization criteria and dosing/monitoring requirements for Aduhelm (aducanumab) IV for AvMed members; applies to prescribers and administering facilities seeking coverage for Aduhelm infusions.

    Policy Summary
    PayerAvMed
    PolicyAduhelm (aducanumab) prior authorization — medical necessity and monitoring criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for Aduhelm (J0172); initial approvals are for 6 months (6 infusions).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial auth duration
    6 monthsContinuation auth
    10 mg/kgMax maintenance dose
    pre-5/7/9/12MRI monitoring
    ≤4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ARIA-H mild threshold

    Coverage Criteria for Aduhelm (aducanumab)

    inv-01: Initial Authorization

    Covered when ALL of the following are met

    Prescriber and age: Prescribed by or in consultation with a neurologist AND member is 50 years of age or older

    See initial authorization requirements

    Diagnosis severity: Confirmed diagnosis of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia based on ONE of the following with baseline documentation: CDR-GS 0.5; MMSE 24-30; RBANS delayed memory index ≤85; MoCA 19.0-25; OR chart-documented signs of MCI

    Submit baseline dementia rating scale results and chart notes ruling out alternate diagnoses

    Amyloid confirmation: Provider must submit documentation of beta-amyloid protein deposition demonstrated by a positive amyloid PET scan

    Amyloid PET required

    MRI and hemorrhage limits: Recent brain MRI within the last year demonstrating all of: no brain hemorrhage >1 cm in past year; fewer than 10 brain microhemorrhages; no localized superficial siderosis; and no relevant brain hemorrhage, bleeding disorder, cerebrovascular abnormalities, or recent (within prior year) unstable cardiovascular condition

    Submit MRI results

    No recent major events/medications: No stroke, TIA, or unexplained loss of consciousness in past 12 months AND not currently receiving antiplatelet agents (except prophylactic aspirin), anticoagulants (e.g., Factor Xa inhibitors), or antithrombins (e.g., heparin)

    Medication and event history required

    Organ function and psychiatric stability: No impaired renal or liver function AND no clinically significant unstable psychiatric illness in the past 6 months

    Clinical assessment required

    Risk counseling: Provider attests that counseling was provided on the risk of amyloid-related imaging abnormalities (ARIA-E and ARIA-H) and member/caregiver are aware to monitor for headache, dizziness, visual disturbances, nausea, and vomiting

    Documentation of counseling required

    inv-02: Continuation of Therapy

    Covered when ALL of the following are met (continuation of therapy)

    Prior exposure and authorization cadence: Continuation approvals are for 6 months; infusion counts and approval limits follow specified rules based on total prior infusions (rules for <5, <6, <8, <12, >12 total infusions). Infusions administered every 4 weeks (at least 21 days apart). If an infusion is missed, resume at same dose as soon as possible.

    See continuation scheduling details

    Ongoing benefit: Member continues to meet initial authorization criteria AND demonstrates response to therapy or has not had clinically meaningful cognitive deterioration compared to pretreatment baseline as measured by one of the specified assessments (CDR-GS or CDR-SB, MMSE, RBANS, MoCA) OR has not progressed to moderate or severe dementia

    Submit follow-up assessment results

    MRI monitoring schedule: Member has received follow-up MRIs for ARIA monitoring at pre-5th, pre-7th, pre-9th, pre-12th infusions and every 6 months thereafter; MRI results must be submitted and meet specified acceptability/stability criteria

    Submit MRIs at specified timepoints

    inv-03: Dosing and ARIA management

    Dosing schedule: Titration schedule: Infusions 1–2: 1 mg/kg; Infusions 3–4: 3 mg/kg; Infusions 5–6: 6 mg/kg; Infusion 7 and beyond: 10 mg/kg (maximum 10 mg/kg). Infusions administered IV over ~1 hour every 4 weeks (maximum dose every 21 days).10 mg/kg maximum

    Follow recommended dosing schedule and vial information

    ARIA dosing interruptions: Follow label-based ARIA management: suspend dosing for specified ARIA severities until radiographic resolution or stabilization and symptom resolution as guided by MRI and clinical judgment. If dosing is resumed after temporary suspension, it may resume at the same dose and titration schedule prior to suspension; consider benefit of reaching/maintaining 10 mg/kg when evaluating suspension. Specific suspension/continuation rules vary by ARIA-E and ARIA-H severity and symptom status per label tables.

    See label recommendations for ARIA-E and ARIA-H dosing decisions

    AvMed limits Aduhelm use to patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia. The policy states there is insufficient evidence to support Aduhelm for moderate or severe Alzheimer's disease, and all listed clinical criteria must be met and documented for coverage consideration.

    AvMed considers the current evidence insufficient to determine that Aduhelm improves health outcomes. Coverage is available only when the member satisfies the policy’s specified medical necessity criteria and all required supporting documentation (labs, diagnostics, chart notes) is submitted; incomplete documentation may lead to denial.

    Coding and ARIA Thresholds

    Covered HCPCS Codes (drug requested)HCPCSCovered
    J0172Aduhelm (aducanumab) injection, intravenous
    inv-07: ARIA-H microhemorrhage thresholds
    Mild≤4 new microhemorrhages
    Moderate5–9 new microhemorrhages
    Severe≥10 new microhemorrhages
    inv-08: ARIA-E size thresholds
    MildSingle site FLAIR <5 cm
    Moderate5–10 cm OR multiple sites each <10 cm
    Severe>10 cm or extensive involvement (significant subcortical white matter and/or sulcal involvement)

    Provider Requirements and Prior Authorization Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization required — A prior authorization is required for Aduhelm (aducanumab) IV (J0172); initial approvals are for 6 months (6 infusions).

    Step Therapy

    Samples and Prior Therapy Verification

    Samples and prior therapy verification — Use of drug samples to initiate therapy does not meet step edit/preauthorization criteria. Previous therapies will be verified through pharmacy paid claims or submitted chart notes; samples cannot be used to satisfy step-therapy or prior-authorization requirements.

    • Use of samples to initiate therapy does not meet step edit/preauthorization criteria.
    • Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

    Background

    Aduhelm is a monoclonal antibody targeting beta-amyloid that received FDA approval through the Accelerated Approval Pathway based on reduction in amyloid plaques. Continued approval is contingent on confirmatory trials; until clinical benefit is verified, AvMed requires adherence to the policy’s detailed eligibility, dosing, monitoring, and documentation requirements for any authorization.

    Definitions and Classifications

    inv-14: Accelerated approval
    Approval pathwayApproved under the FDA Accelerated Approval Pathway based on reduction in amyloid beta plaques
    StatusHas not received traditional (full) FDA approval
    Condition for continued approvalContinued approval contingent on verification of clinical benefit in a confirmatory trial
    inv-15: ARIA classifications
    ARIA categoriesIncludes ARIA-E (edema/effusion) and ARIA-H (microhemorrhage and superficial siderosis)
    ARIA-E radiographic severityMild: FLAIR hyperintensity confined to sulcus and/or cortex/subcortical white matter in one location <5 cm; Moderate: 5–10 cm or >1 site each <10 cm; Severe: >10 cm or extensive involvement
    Policy Summary
    PayerAvMed
    PolicyAduhelm (aducanumab) prior authorization — medical necessity and monitoring criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for Aduhelm (J0172); initial approvals are for 6 months (6 infusions).
    SourceLink
    On This Page
    Coverage Criteria for Aduhelm (aducanumab)Coding and ARIA ThresholdsProvider Requirements and Prior Authorization ActionsBackgroundDefinitions and Classifications
    ARIA MRI outcome criteria: MRI results must meet ONE of the specified ARIA criteria: for ARIA-E — no new ARIA-E OR mild asymptomatic ARIA-E; moderate or severe ARIA-E may be acceptable if asymptomatic and stable or if symptomatic but stable (conditions apply). For ARIA-H microhemorrhage — 1–4 new microhemorrhages (asymptomatic), 5–9 new if asymptomatic and stabilized, or 1–9 new if symptomatic and stabilized. For superficial siderosis — no new areas OR 1 (asymptomatic) OR 2 (asymptomatic and stabilized) OR 1–2 that resulted in symptoms if stabilized.

    See ARIA MRI Classification Criteria and stability requirements

    Documentation Required

    Required Clinical Documentation

    Required clinical documentation — Submit baseline dementia rating scale results (e.g., CDR-GS, MMSE, RBANS, MoCA), positive amyloid PET documentation, recent brain MRI results, and follow-up MRIs as specified for ARIA monitoring. Provider must also submit chart notes ruling out alternative diagnoses and documenting signs/symptoms of mild cognitive impairment when applicable.

    Denial Risk

    Incomplete Documentation Risk

    Incomplete documentation risk — Authorization can be delayed or denied if request information is incomplete, incorrect, or illegible. Ensure all supporting documentation (labs, diagnostic reports, MRI and PET results, baseline and follow-up cognitive testing, provider chart notes, prescriber signature and contact information) is included with the request to avoid processing delays.

    • Authorization can be delayed or denied if information is incomplete, incorrect, or illegible.
    • Include prescriber signature (no preprinted stamps), phone and fax numbers, MRI/PET reports, baseline and follow-up cognitive test results, and relevant chart notes.
    ARIA-H radiographic severityMicrohemorrhage Mild: ≤4 new; Moderate: 5–9 new; Severe: ≥10 new; Superficial siderosis Mild: 1 focal area; Moderate: 2 focal areas; Severe: >2 focal areas